VA-INTELSAT
23.3.2022 14:02:14 CET | Business Wire | Press release
Intelsat , operator of the world’s largest integrated satellite and terrestrial network and leading provider of inflight connectivity (IFC), is donating a pioneering piece of satellite history to the Smithsonian’s National Air and Space Museum in Washington, DC. The company will transfer the ground spare of the Intelsat 1 satellite in a ceremony today at the museum’s Steven F Udvar-Hazy Center near Washington Dulles International Airport.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220323005147/en/
Intelsat 1, also known as Early Bird, was the first commercial communications satellite in geosynchronous orbit launched April 6, 1965. During the early age of space technology, two identical satellites were often constructed in the event of launch failure. Today’s donation is a fully constructed satellite that had been on display at Intelsat’s U.S. headquarters.
Through its four years of service, Intelsat 1 played a historic role in connecting humanity. It is credited with broadcasting the Apollo 11 moon landing to millions of TV viewers around the world, doubling the number of telephone lines between the continents, and providing other critical telecommunications and broadcasting services. Intelsat 1 was also the first satellite to provide direct and nearly instantaneous contact between Europe and North America.
“This historic satellite’s new home commemorates its role in some of the most profound moments in human space exploration and global connectivity. Allowing people to witness the moon landing live inspired a generation of space explorers and enthusiasts. This reminder of Intelsat’s integral part in driving humanity forward only underscores how far Intelsat has come today and will continue to go in connecting our world,” said Intelsat CEO Stephen Spengler.
“We are excited to collect the ground spare of the first commercial communications satellite to be placed in geosynchronous orbit,” said Jim David, curator at the National Air and Space Museum. “The Intelsat 1 satellite will be a featured among iconic artifacts like the Hubble space telescope and Skylab in a new exhibition opening in 2025.”
The satellite will be restored and prepared for exhibition at the museum’s Steven F. Udvar-Hazy Center in Chantilly, Virginia. The satellite will eventually be displayed among other spacecraft in a new exhibition, scheduled to open in 2025, as part of the museum’s renovation of its building in Washington, DC.
Intelsat 1 emphasizes Intelsat’s role as the foundational architect of satellite technology – past, present and future. Intelsat's mission is to make broadband more accessible worldwide. With a 50-year record of delivering seamless and secure coverage to government and industry leaders across 200+ countries, the company is investing $2B, initially, to build a unified, global network that will support virtually any access technology, enabling the next generation of global mobility, IoT and 5G services.
To learn more about Early Bird’s history, click here .
For media b-roll, click here .
About Intelsat
As the foundational architects of satellite technology, Intelsat operates the world’s most trusted satellite telecom network. We apply our unparalleled expertise and global scale to connect people, businesses, and communities, no matter how difficult the challenge. Intelsat is building the future of global communications with the world’s first hybrid, multi-orbit, software-defined 5G network designed for simple, seamless, and secure coverage precisely when and where our customers most need it. Follow the leader in global connectivity and “Imagine Here,” with us, at Intelsat.com .
Follow Us on Social Media
:
Twitter
| LinkedIn
| Facebook
| Instagram
| YouTube
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005147/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
